The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies

Mkhitaryan E.A.

Pirogov Russian National Research Medical University;
Russian Gerontology Research and Clinical Centre — Pirogov Russian National Research Medical University

Levin O.S.

Russian Medical Academy of Continuous Professional Education;
S.P. Botkin City Clinical Hospital

Cognitive impairment in cerebrovascular diseases

Authors:

Bogolepova A.N., Mkhitaryan E.A., Levin O.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4‑2): 12‑16

DOI: 10.17116/jnevro202412404212

Read: 3742 times

Download PDF (RU)
Contact the author
Table of contents

COGNITIVE IMPAIRMENT IN CEREBROVASCULAR DISEASES
COGNITIVE IMPAIRMENT IN CEREBROVASCULAR DISEASES

To cite this article:

Bogolepova AN, Mkhitaryan EA, Levin OS. Cognitive impairment in cerebrovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4‑2):12‑16. (In Russ.)
https://doi.org/10.17116/jnevro202412404212

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10
Effe­ctiveness of comprehensive reha­bilitation of patients after a stroke in terms of changes in clinical and functional characteristics. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):11-16
Methods for dete­rmining the extent of ischemic changes in brain matter in the prognosis of clinical outcome after successful thro­mboextraction. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):17-27
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
Gender aspe­cts of atte­ntion defi­cit hype­ractivity diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):70-75
Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83
The expe­rience of diagnosing Alzheimer’s disease based on the study of cere­brospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
Cognitive vascular diso­rders and morphometric para­meters of the prefrontal, dorsolateral cortex and thalamus in post-stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):91-95
Prevalence of cere­brovascular diseases risk factors acco­rding to the cohort survey data in Bishkek, Kyrgyz Repu­blic. Russian Journal of Preventive Medi­cine. 2025;(3):34-39
Abstract:

Cognitive impairment, which is highly prevalent, especially among older people, leads to a decrease in the quality of life of patients, impairment of daily activities, and an increased risk of dementia and mortality. Currently, much attention is paid to mild cognitive impairment. The article discusses diagnostic criteria and possible clinical variants of this syndrome. Given the high rate of progression of mild cognitive impairment to dementia, it is necessary to identify risk groups and carry out therapeutic preventive measures. Correction of potentially modifiable risk factors is considered as a promising direction of therapy. Sufficient physical and mental activity, proper diet, normalization of sleep, visual acuity and hearing are necessary. Preventing stroke and controlling vascular risk factors may reduce the risk of mild cognitive impairment progressing to dementia.

Keywords:

vascular cognitive impairment
dementia
stroke
vascular risk factors
therapy
Prospekta

Authors:

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies

Mkhitaryan E.A.

Pirogov Russian National Research Medical University;
Russian Gerontology Research and Clinical Centre — Pirogov Russian National Research Medical University

Levin O.S.

Russian Medical Academy of Continuous Professional Education;
S.P. Botkin City Clinical Hospital

Received:

21.02.2024

Accepted:

21.02.2024

Close metadata

References:

  1. Chang WE, Chang CH. Vascular Cognitive Impairment and Dementia. Continuum (Minneap Minn). 2022;28(3):750-780.  https://doi.org/10.1212/CON.0000000000001124
  2. Boyle PA, Yu L, Wilson RS, et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83(1):74-83.  https://doi.org/10.1002/ana.25123
  3. Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-281.  https://doi.org/10.1212/01.WNL.0000149519.47454.F2
  4. Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc. 2004;52(2):195-204.  https://doi.org/10.1111/j.1532-5415.2004.52058.x
  5. Zlokovic BV, Gottesman RF, Bernstein KE, et al. Vascular contributions to cognitive impairment and dementia (VCID): a report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimer’s & Dementia. 2020;16(12):1714-1733. https://doi.org/10.1002/alz.12157
  6. Toth P, Tarantini S, Csiszar A, et al. Functional vascular contributions to cognitive impairment and dementia: mechanisms and consequences of cerebral autoregulatory dysfunction, endothelial impairment, and neurovascular uncoupling in aging. Am J Physiol Heart Circ Physiol. 2017;312(1):H1-20.  https://doi.org/10.1152/ajpheart.00581.2016
  7. Wen W, Sachdev PS, Li JJ, et al. White matter hyperintensities in the forties: their prevalence and topography in an epidemiological sample aged 44—48. Hum Brain Mapp. 2009;30(4):1155-1167. https://doi.org/10.1002/hbm.20586
  8. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry. 2001;70(1):9-14.  https://doi.org/10.1136/jnnp.70.1.9
  9. Dhamoon MS, Cheung Y-K, DeRosa JT, et al. Association between subclinical brain infarcts and functional decline trajectories. J Am Geriatr Soc. 2018;66(11):2144-2150. https://doi.org/10.1111/jgs.15557
  10. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-1222. https://doi.org/10.1056/NEJMoa022066
  11. Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010;41(4):600-606.  https://doi.org/10.1161/STROKEAHA.109.570044
  12. Dong C, Nabizadeh N, Caunca M, et al. Cognitive correlates of white matter lesion load and brain atrophy: the Northern Manhattan Study. Neurology. 2015;85(5):441-449.  https://doi.org/10.1212/WNL.0000000000001716
  13. Arvanitakis Z, Leurgans SE, Barnes LL, et al. Microinfarct pathology, dementia, and cognitive systems. Stroke. 2011;42(3):722-727.  https://doi.org/10.1161/STROKEAHA.110.595082
  14. Cao L, Tan L, Wang H-F, et al. Cerebral microinfarcts and dementia: a systematic review and metaanalysis. Curr Alzheimer Res. 2017;14(7):802-808.  https://doi.org/10.2174/1567205013666161201200429
  15. Skrobot OA, O’Brien J, Black S, et al. The Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2017;13(6):624-633.  https://doi.org/10.1016/j.jalz.2016.10.007
  16. Pendlebury ST, Cuthbertson FC, Welch SJV, et al. Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke. 2010;41(6):1290-1293. https://doi.org/10.1161/STROKEAHA.110.579888
  17. Erkinjuntti T. Clinical criteria for vascular dementia: the NINDS-AIREN criteria. Dementia. 1994;5(3-4):189-192.  https://doi.org/10.1159/000106721
  18. Zhao L, Biesbroek JM, Shi L, et al. Strategic infarct location for post-stroke cognitive impairment: a multivariate lesion-symptom mapping study. J Cereb Blood Flow Metab. 2018;38(8):1299-1311. https://doi.org/10.1177/0271678X17728162
  19. Esin RG, Safina DR, Khakimova AR, et al. Neuroinflammation and neuropathology. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(4):107-112. (In Russ.). https://doi.org/10.17116/jnevro2021121041107
  20. Zaręba-Kozioł M, Burdukiewicz M, Wysłouch-Cieszyńska A. Intracellular Protein S-Nitrosylation-A Cells Response to Extracellular S100B and RAGE Receptor. Biomolecules. 2022;12(5):613.  https://doi.org/10.3390/biom12050613
  21. Sorci G, Riuzzi F, Arcuri C, et al. S100B protein in tissue development, repair and regeneration. World J Biol Chem. 2013;4(1):1-12.  https://doi.org/10.4331/wjbc.v4.i1.1
  22. Donato R, Sorci G, Riuzzi F, et al. S100B’s double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):1008-1022. https://doi.org/10.1016/j.bbamcr.2008.11.009
  23. Baudier J, Gentil BJ. The S100B Protein and Partners in Adipocyte Response to Cold Stress and Adaptive Thermogenesis: Facts, Hypotheses, and Perspectives. Biomolecules. 2020;10(6):843.  https://doi.org/10.3390/biom10060843
  24. Ostendorp T, Leclerc E, Galichet A, et al. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J. 2007;26(16):3868-3878. https://doi.org/10.1038/sj.emboj.7601805
  25. Uspenskaya YuA, Komleva YuK, Pozhilenkova EA, et al. Ligands of RAGE-Proteins: Role in Intercellular Communication and Pathogenesis of Inflammation. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk = Annals of the Russian Academy of Medical Sciences. 2015;70(6):694-703. (In Russ.). https://doi.org/10.15690/vramn566
  26. Leclerc E, Sturchler E, Vetter SW. The S100B/RAGE Axis in Alzheimer’s Disease. Cardiovasc Psychiatry Neurol. 2010;2010:539581. https://doi.org/10.1155/2010/539581
  27. Bongarzone S, Savickas V, Luzi F, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017;60(17):7213-7232. https://doi.org/10.1021/acs.jmedchem.7b00058
  28. Bianchi R, Kastrisianaki E, Giambanco I, et al. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem. 2011;286(9):7214-7226. https://doi.org/10.1074/jbc.M110.169342
  29. Ghatak S, Dolatabadi N, Gao R, et al. NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models. Mol Psychiatry. 2021;26(10):5751-5765. https://doi.org/10.1038/s41380-020-0776-7
  30. Wilder PT, Varney KM, Weber DJ. Targeting S100 Calcium-Binding Proteins with Small Molecule Inhibitors. Methods Mol Biol. 2019;1929:291-310.  https://doi.org/10.1007/978-1-4939-9030-6_19
  31. Instructions for the medical use of the drug Prospecta. Date of access: 02/15/2024. (In Russ.). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0c47ac45-d055-4879-b8f3-bf6d2400318f
  32. Belova AN, Bogdanov EI, Voznyuk IA, et al. Therapy of moderate cognitive impairment in the early recovery period of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(5):33-39. (In Russ.). https://doi.org/10.17116/jnevro202112105133
  33. Ostroumova OD, Ebzeeva EYu, Polyakova OA, et al. Therapy of asthenia in patients after acute novel coronavirus infection (COVID-19): results of a multicenter, randomized, double-blind, placebocontrolled clinical study. Therapy. 2022;8(8):146-157. (In Russ.). https://doi.org/10.18565/therapy.2022.8.146-157
  34. Tkacheva ON, Mkhitaryan EA, Kolykhalov IV, et al. Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2023;123(7):41-49. (In Russ.). https://doi.org/10.17116/jnevro202312307141
  35. Khasanova DR, Yakupova AA, Kamchatnov PR, et al. Therapy of cognitive impairment in patients with cerebral infarction in the internal carotid artery system: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1):24-32. (In Russ.). https://doi.org/10.14412/2074-2711-2024-1-24-32
  36. Levin OS, Kovalchuk VV, Putilina MV, et al. Treatment of mild cognitive impairment of various origins in patients with chronic somatic diseases: results of a multicenter open prospective observational program (PARUS). Effective Pharmacotherapy. Neurology and Psychiatry. 2022;18(43):78-83. (In Russ.).
  37. Shvartsman GI, Skoromets AA, Zhivolupov SA, et al. Therapy of moderate cognitive impairment and asthenia in patients with cerebrovascular pathology: results of a prospective observational study. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(8):82-88. (In Russ.). https://doi.org/10.17116/jnevro202212208188
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.